Dr Pant Discusses Next Steps in Daraxonrasib Development for Pancreatic Cancer

In this video, Shubham Pant, MD, MBBS, discusses what comes next in the clinical development of daraxonrasib (Rasonque), building on the RASolute 302 trial (NCT06625320). He outlines 2 additional studies in the RASolute program that are moving the drug into earlier points in the pancreatic cancer treatment journey.

The first, RASolute 303, is enrolling treatment-naive patients with metastatic pancreatic cancer. This trial is testing daraxonrasib as a single agent, as well as daraxonrasib in combination with gemcitabine and nab-paclitaxel, against the current standard regimen of gemcitabine and nab-paclitaxel alone. By studying the drug in the frontline metastatic setting, this trial is designed to determine whether daraxonrasib can improve outcomes for patients before they've received any prior systemic therapy, both on its own and layered onto existing chemotherapy backbones.

The second, RASolute 304, moves even earlier in the disease course. This trial enrolls patients with early-stage, resected pancreatic cancer who have already completed adjuvant therapy. After finishing that standard treatment, patients are randomized to either standard-of-care follow-up or daraxonrasib, evaluating whether the drug has a role in this postadjuvant maintenance-type setting for patients whose disease has been surgically removed.

Together, Pant frames these two trials as representing the "early stages" of daraxonrasib's development pipeline in pancreatic cancer: one addressing the very earliest, resected disease population immediately after adjuvant treatment, and the other addressing front-line, treatment-naive patients once the cancer has become metastatic. He expresses enthusiasm about this next phase of investigation, positioning RASolute 303 and RASolute 304 as complementary efforts to understand where daraxonrasib fits across the pancreatic cancer treatment continuum, from resected early-stage disease through metastatic, treatment-naive presentations.